Cervical lymphatic bypass for treating Alzheimer's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates a novel surgical approach called deep cervical lymph node to venous bypass (DCLNV-BP) aimed at treating Alzheimer's disease by addressing the accumulation of neurotoxic proteins in the brain. The procedure is based on recent findings regarding the glymphatic system and its role in neuroinflammation and cognitive decline. Participants diagnosed with mild to moderate Alzheimer's disease will undergo this intervention to evaluate its safety and potential efficacy. The study aims to provide an alternative to existing pharmacotherapies that offer limited benefits and significant side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of mild-moderate Alzheimer's disease (based on NIA-AA criteria);
* Mini-Mental State Examination (MMSE) score 10-22;
* Both participants and caregiver are able to understand English or Mandarin
* Ability to provide informed consent or have a legally authorised representative to provide informed consent;
* Good family support for post-treatment care and rehabilitation;
* Fit for general anaesthesia/deep sedation and surgery (ASA 1-2; excluding the diagnosis of Alzheimer's Disease).

Exclusion Criteria:

* Cognitive decline due to prior infection or autoimmune diseases;
* History of major cerebrovascular events or significant cardiovascular diseases;
* Inability to have the head turned passively by at least 40 degrees;
* Previous neck lymph node surgery or irradiation;
* Active infection or malignancy;
* Any contraindications to surgery or lumbar puncture
* Any contraindication to MRI/PET scan (eg. metallic implant that are not MRI-safe, known radiotracer allergy)
* Experimental Alzheimer's Disease treatment within the past 6 months. • Current use of monoclonal antibodies treatment (eg. lecanemab/donanemab)

Where it's running

• Changi General Hospital
  Singapore, Singapore Recruiting

Study contacts

• Study coordinator: Vincent KS Tay, MD, FAMS
• Email: vincent.tay.k.s@singhealth.com.sg
• Phone: +65 6788 8833

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using deep rTMS to improve memory in Alzheimer's Disease

  This study is testing if a new brain treatment called deep rTMS can help improve memory in people with mild to moderate Alzheimer's Disease.

  Recruiting Phase 1/2 University of California, Los Angeles · Los Angeles, California · NCT06597942

• Screening for financial hardship in Alzheimer's and dementia patients

  This study is trying to understand the financial struggles faced by people with Alzheimer's and their caregivers to see how it affects their well-being and care choices.

  Recruiting Fred Hutchinson Cancer Center · Seattle, Washington · NCT06922188

• Brain PET imaging with [18F]Fluorbetazine to see amyloid plaques in people with normal thinking, MCI, or Alzheimer’s

  This study tests a PET scan using [18F]Fluorbetazine to see if it can reliably detect amyloid plaques in the brain across people with normal cognition, MCI, or Alzheimer's disease.

  Recruiting Phase 3 HTA Co., Ltd. · Beijing, Beijing Municipality · NCT07764679

• Treatments for sustained improvement in symptomatic Alzheimer’s disease (18 months)

  This trial tests whether adding atomoxetine or metformin to standard care helps people with Alzheimer’s disease or related dementia see lasting improvements over 18 months.

  Recruiting at 2 sites Phase 3 University College, London · Cambridge and 1 other locations · NCT07724132

• Carotid artery wall viscosity and memory problems in older adults

  This project will test whether the viscous behavior of the carotid artery wall is linked to memory problems in people over 70 with memory complaints, Alzheimer's disease, or vascular dementia.

  Recruiting University Hospital, Rouen · Rouen · NCT07205003

• DUVAX: a first-in-human vaccine for amyloid and tau targets in adults 40-65

  A first-in-human vaccine called DUVAX is tested in healthy adults to see if it's safe and whether it triggers an immune response against Alzheimer’s-related proteins.

  Recruiting Phase 1 Nuravax, Inc. · Miami Lakes, Florida · NCT07142278

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.